Friday, October 23, 2020
Home Life Style Health & Fitness This Antibody Therapy Can Cut Covid-19 Hospitalisation Risk

This Antibody Therapy Can Cut Covid-19 Hospitalisation Risk

The Phase 2 study of the BLAZE-1 clinical trial evaluated LY-CoV555, a SARS-CoV-2 neutralising antibody, for the treatment of symptomatic Covid-19 in the outpatient setting

Raising hope of Covid-19 treatment at an early stage, an antibody therapy has been found to quickly reduce SARS-CoV-2 viral load in newly infected patients and cut hospitalisation risk, US-based pharmaceutical company Eli Lilly said, while revealing interim results of a clinical trial.

The Phase 2 study of the BLAZE-1 clinical trial evaluated LY-CoV555, a SARS-CoV-2 neutralising antibody, for the treatment of symptomatic Covid-19 in the outpatient setting, the company said on Wednesday.

The trial enrolled mild-to-moderate recently diagnosed Covid-19 patients across four groups –placebo, 700 mg, 2800 mg, and 7000 mg.

Follow NewsGram on LinkedIn to know what’s happening around the world.

Analyses of viral data demonstrated that LY-CoV555 improved viral clearance at an earlier time point — day 3 — and reduced the proportion of patients with persistently high viral load at later time points.

Most study hospitalisations occurred in patients with underlying risk factors — age or body mass index (BMI) — suggesting a more pronounced treatment effect for patients in these higher-risk groups.

Ongoing studies will seek to confirm this finding, the drugmaker said.

Antibody treatment found to cut Covid hospitalisation risk
Most study hospitalisations occurred in patients with underlying risk factors like age or body mass index (BMI). Unsplash

Across all treatment groups, including placebo, no patients progressed to mechanical ventilation or died, the results showed.

Exploratory analyses indicated a more rapid improvement in symptoms for patients treated with LY-CoV555 versus placebo, supporting the hospitalisation effect.

The treatment was well-tolerated, with no drug-related serious adverse events reported.

“These interim data from the BLAZE-1 trial suggest that LY-CoV555, an antibody specifically directed against SARS-CoV-2, has a direct antiviral effect and may reduce Covid-related hospitalisations,”

Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories, said in a statement.

“The results reinforce our conviction that neutralising antibodies can help in the fight against Covid-19.”

The company said it intends to quickly publish the results of this interim analysis in a peer-reviewed journal and discuss appropriate next steps with global regulators.

Antibody treatment found to cut Covid hospitalisation risk
The treatment was well-tolerated, with no drug-related serious adverse events reported. (Representational Image). Unsplash

If proved to be effective in further analyses, this could be the first potential treament for Covid-19 patients with mild and moderate level of severity.

Also Read: Food for Paws: An Initiative to Provide Sustenance to Strays Across India

This is because the drug remdesivir and the steroid dexamethasone have been found to be helpful in treatment of patients with serious illness.

The BLAZE-1 clinical trial remains ongoing, testing LY-CoV555 in combination with a second Lilly antibody, LY-CoV016, which binds a different epitope in the SARS-CoV-2 spike region.A

The trial is currently enrolling a larger, confirmatory cohort of higher risk patients, testing the ability of the antibody combination to reduce the number of patients with persistently high viral load and reduce Covid-related hospitalisations. (IANS)

STAY CONNECTED

19,120FansLike
362FollowersFollow
1,781FollowersFollow

Most Popular

Down Syndrome May Increase COVID Death Risk

Researchers have found that down syndrome is associated with a 10-fold increased risk for COVID-19-related death. Down syndrome (sometimes called Down's syndrome) is a condition...

Miss India 2020 Pageant Held Virtually Due to Pandemic

In the wake of the COVID-19 pandemic, Miss India 2020 pageant will be held virtually the Miss India Organisation has announced. A nationwide audition to...

6 Designers Came Together to Help Craft Clusters Impacted by Pandemic

Six fashion designers came together to support marginalized craft clusters and those heavily impacted by the pandemic by generating livelihood opportunities for the artisans....

India Rapidly Expanding High Power Supercomputers

India is fast expanding its supercomputer facilities and developing the capacity to manufacture its own supercomputers in the country, the Ministry of Science and...

Cholesterol Medications May Lower Cancer-Related Deaths in Women

Among women with breast cancer, colorectal cancer, or melanoma, those who are taking cholesterol-lowering medications are less likely to die from cancer, researchers said. The...

Immediate Biomedical Waste Management Halts COVID Spread: UNIDO

The United Nations Industrial Development Organisation (UNIDO) on Tuesday stressed the need to halt the spread of COVID-19 through all possible infection channels, including...

1.16L Infant Deaths in 2019 Due to Air Pollution in India

The first-ever comprehensive analysis of air pollution's global impact on newborns finds that outdoor and household particulate matter pollution contributed to the deaths of...

Literature and Movies: Filmmaker Suman Mukhopadhyay

While reading 'Chuti Nakoch', a story by writer Ashapurna Devi, he suddenly felt grabbed by the jugular. It was tough to ignore the visual...

Recent Comments